| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000047557 |
| Receipt No. | R000054236 |
| Scientific Title | Evaluation of the effect of flaxseed lignan on menopausal symptoms |
| Date of disclosure of the study information | 2022/06/19 |
| Last modified on | 2022/10/24 (Ver. 2) |
| Basic information | ||
| Public title | Evaluation of the effect of flaxseed lignan on menopausal symptoms | |
| Acronym | Evaluation of the effect of flaxseed lignan on menopausal symptoms | |
| Scientific Title | Evaluation of the effect of flaxseed lignan on menopausal symptoms | |
| Scientific Title:Acronym | Evaluation of the effect of flaxseed lignan on menopausal symptoms | |
| Region |
|
|
| Condition | ||
| Condition | healthy person | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To examine the effect of continuous intake of flaxseed lignan (secoisolariciresinol diglucoside: SDG) on menopausal symptoms. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The simplified menopausal index (SMI) test |
| Key secondary outcomes | Questionnaires related to menopausal symptoms |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Secoisolariciresinol diglucoside (SDG) low dose capsule (2 capsules per day) | |
| Interventions/Control_2 | Secoisolariciresinol diglucoside (SDG) high dose capsule (2 capsules per day) | |
| Interventions/Control_3 | Placebo food (2 capsules per day) | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | (1) Females between the ages of 35-60 years at the time of consent.
(2) Those who are able to consume the test meal continuously. (3) Those who are in the transitional period (less than 3 years from the last menstrual period) or after menopause (less than 3 years from the last menstrual period). (4) Those who have subjective symptoms related to menopause (5) Simplified Menopausal Index (SMI): 26 points or more. (6) Those who can avoid binge drinking and excessive exercise during the study period and lead the same lifestyle (diet, exercise, etc.) as before the study period. (7) Those who have received sufficient explanation of the purpose and content of this study, have the ability to consent, and can voluntarily volunteer to participate with a good understanding of the study, and agree to participate in this study in writing. (8) Those who receive no medication. |
|||
| Key exclusion criteria | (1) Those who have food allergy.
(2) Those who are pregnant or lactating, or plan to become pregnant or lactate during the study. (3) Those who have participated in other clinical studies within 3 months of consent and those who plan to participate in other clinical studies during the study period. (4) Those who have undergone oophorectomy or hysterectomy. (5) Those with extremely irregular diets or irregular sleep rhythms (e.g., Night and day shift worker). (6) Those who regularly use medicines, food for specified health use, functional food, or health food that may affect the evaluation items. (7) Those who have been taking hormone therapy. (8) Those who excessively smoke or excessively consume alcohol. (9) Those who are undergoing treatment for a disease, or have a history of a serious disease that required medication. (10) Patients with serious diseases such as diabetes, hepatic disease, renal disease, or cardiac disease, or those with a history of such diseases. (11) Those who are judged to be inappropriate as subjects based on the answers to various questionnaires. (12) Others, who are judged by the principal investigator to be inappropriate as subjects. |
|||
| Target sample size | 150 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | NIPPN CORPORATION | ||||||
| Division name | Innovation Center, Central Research Laboratory | ||||||
| Zip code | 243-0041 | ||||||
| Address | 5-1-3 Midorigaoka, Atsugi City, Kanagawa Prefecture | ||||||
| TEL | 042-222-6963 | ||||||
| miyashita@nippn.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Macromill, Inc. | ||||||
| Division name | Secretariat "Evaluation test for menopausal symptom improvement by flax lignan | ||||||
| Zip code | 108-0075 | ||||||
| Address | F11, Shinagawa East One Tower, 2-16-1, konan, Minato-ku, Tokyo | ||||||
| TEL | 0120-998-017 | ||||||
| Homepage URL | |||||||
| monitor@terra-k.co.jp | |||||||
| Sponsor | |
| Institute | Macromill, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | NIPPN CORPORATION |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Ueno-Asagao Clinic Ethical Review Committee |
| Address | 6F, 2-7-5 Higashiueno, Taito-ku, Tokyo |
| Tel | 03-6240-1162 |
| jimukyoku@tes-h.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054236 |